Table 1:
Cohort characteristics and distribution of APOE genotypes in study populations
| Controls | AD | PD | CBD | LBD | MSA | PSP | |
|---|---|---|---|---|---|---|---|
| N | 591 | 571 | 348 | 41 | 525 | 223 | 202 |
| Mean Age ± SD (years)a | 71.7 ± 11.0 | 81.8 ± 10.1 | 78.2 ± 9.4 | 74.8 ± 9.3 | 77.5 ± 8.2 | 66.1 ± 10.8 | 78.1 ± 9.7 |
| Age range (years)a | (50, 105) | (41, 103) | (19, 107) | (51, 96) | (49, 99) | (20, 90) | (55, 102) |
| No. Male (%) | 318 (53.8) | 221 (38.7) | 234 (67.2) | 18 (43.9) | 338 (64.4) | 109 (48.9) | 113 (55.9) |
| No. Female (%) | 273 (46.2) | 350 (61.3) | 114 (32.8) | 23 (56.1) | 187 (35.6) | 114 (51.1) | 89 (44.1) |
| No. Pathologically-confirmed | 218 (36.9) | 571 (100) | 348 (100) | 41 (100) | 525 (100) | 223 (100) | 202 (100) |
| No. Clinically-defined | 373 (63.1)b | N/A | N/A | N/A | N/A | N/A | N/A |
| No. with ε2/ε2 (%) | 5 (0.8) | 0 (0) | 0 (0) | 0 (0) | 2 (0.4) | 0 (0) | 3 (1.5) |
| No. with ε2/ε3 (%) | 83 (14.0) | 29 (5.1) | 54 (15.5) | 4 (9.8) | 35 (6.7) | 25 (11.2) | 20 (9.9) |
| No. with ε2/ε4 (%) | 14 (2.4) | 11 (1.9) | 6 (1.7) | 1 (2.4) | 14 (2.7) | 6 (2.7) | 5 (2.5) |
| No. with ε3/ε3 (%) | 368 (62.3) | 208 (36.4) | 203 (58.3) | 28 (68.3) | 239 (45.5) | 141 (63.2) | 138 (68.3) |
| No. with ε3/ε4 (%) | 104 (17.6) | 252 (44.1) | 82 (23.6) | 6 (14.6) | 187 (35.6) | 48 (21.5) | 33 (16.3) |
| No. with ε4/ε4 (%) | 17 (2.9) | 71 (12.4) | 3 (0.9) | 2 (4.9) | 48 (9.1) | 3 (1.3) | 3 (1.5) |
a
Age was defined as age at death for pathologically-confirmed samples and age at specimen collection for clinically-defined control samples. Age information was available for 590/591 controls, 568/571 AD samples, 342/348 PD samples, 41/41 CBD samples, 523/525 LBD samples, 101/223 MSA samples, and 202/202 PSP samples.
b
DNA from clinically defined control samples was extracted from blood as opposed to brain tissue from all other cohorts.
Abbreviations: AD, Alzheimer’s disease; PD, Parkinson’s disease; CBD, corticobasal degeneration; LBD, Lewy body dementia; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; SD, standard deviation; N/A, not applicable.